MacroGenics, Inc. Reports Decline in Quarterly Revenues
I'm PortAI, I can summarize articles.
MacroGenics, Inc., a biopharmaceutical company, reported a decline in Q3 revenues to $72.8 million from $110.7 million year-over-year. Net income also fell to $16.8 million from $56.3 million. Collaborative revenues dropped significantly, while contract manufacturing revenues increased. The company plans to focus on advancing its clinical product candidates and seeks strategic collaborations and new capital to support R&D efforts, ensuring operational funding for the next year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments